228 related articles for article (PubMed ID: 18452090)
1. Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.
Parekh S; Privé G; Melnick A
Leuk Lymphoma; 2008 May; 49(5):874-82. PubMed ID: 18452090
[TBL] [Abstract][Full Text] [Related]
2. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
[TBL] [Abstract][Full Text] [Related]
3. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
[TBL] [Abstract][Full Text] [Related]
4. Sequential transcription factor targeting for diffuse large B-cell lymphomas.
Cerchietti LC; Polo JM; Da Silva GF; Farinha P; Shaknovich R; Gascoyne RD; Dowdy SF; Melnick A
Cancer Res; 2008 May; 68(9):3361-9. PubMed ID: 18451163
[TBL] [Abstract][Full Text] [Related]
5. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.
Polo JM; Juszczynski P; Monti S; Cerchietti L; Ye K; Greally JM; Shipp M; Melnick A
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3207-12. PubMed ID: 17360630
[TBL] [Abstract][Full Text] [Related]
7. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
8. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
[TBL] [Abstract][Full Text] [Related]
9. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.
Cerchietti LC; Yang SN; Shaknovich R; Hatzi K; Polo JM; Chadburn A; Dowdy SF; Melnick A
Blood; 2009 Apr; 113(15):3397-405. PubMed ID: 18927431
[TBL] [Abstract][Full Text] [Related]
10. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
[TBL] [Abstract][Full Text] [Related]
11. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
Ci W; Polo JM; Cerchietti L; Shaknovich R; Wang L; Yang SN; Ye K; Farinha P; Horsman DE; Gascoyne RD; Elemento O; Melnick A
Blood; 2009 May; 113(22):5536-48. PubMed ID: 19307668
[TBL] [Abstract][Full Text] [Related]
12. B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.
Gu H; He J; Li Y; Mi D; Guan T; Guo W; Liu B; Chen Y
J Med Chem; 2022 Dec; 65(23):15559-15583. PubMed ID: 36441945
[TBL] [Abstract][Full Text] [Related]
13. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
Cardenas MG; Oswald E; Yu W; Xue F; MacKerell AD; Melnick AM
Clin Cancer Res; 2017 Feb; 23(4):885-893. PubMed ID: 27881582
[TBL] [Abstract][Full Text] [Related]
14. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
[TBL] [Abstract][Full Text] [Related]
15. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
Duan S; Cermak L; Pagan JK; Rossi M; Martinengo C; di Celle PF; Chapuy B; Shipp M; Chiarle R; Pagano M
Nature; 2012 Jan; 481(7379):90-3. PubMed ID: 22113614
[TBL] [Abstract][Full Text] [Related]
16. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
[TBL] [Abstract][Full Text] [Related]
17. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
Juszczynski P; Chen L; O'Donnell E; Polo JM; Ranuncolo SM; Dalla-Favera R; Melnick A; Shipp MA
Blood; 2009 Dec; 114(26):5315-21. PubMed ID: 19855081
[TBL] [Abstract][Full Text] [Related]
18. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
[TBL] [Abstract][Full Text] [Related]
19. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
Jiao J; Lv Z; Zhang P; Wang Y; Yuan M; Yu X; Otieno Odhiambo W; Zheng M; Zhang H; Ma Y; Ji Y
Neoplasia; 2020 Mar; 22(3):142-153. PubMed ID: 32062068
[TBL] [Abstract][Full Text] [Related]
20. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.
Cerchietti LC; Ghetu AF; Zhu X; Da Silva GF; Zhong S; Matthews M; Bunting KL; Polo JM; Farès C; Arrowsmith CH; Yang SN; Garcia M; Coop A; Mackerell AD; Privé GG; Melnick A
Cancer Cell; 2010 Apr; 17(4):400-11. PubMed ID: 20385364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
